Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+3.97%
-3.51%
-5.52%
-0.99%
+5.01%
ABBV
AbbVie
$226.87
Login to see AbbVie (ABBV) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Trading below its fair value
Investors confidence is positive
Pays a reliable dividend
Technical Indicators
5+ Days Down
Chart
$222.47 (+1.98%)
$190.83 (+18.89%)
$185.72 (+22.16%)
$201.5 (+12.59%)
ABBV has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Investors losing confidence
ABBV overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a strong earnings
Above analyst estimates
Revenue increase YoY
Earnings increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Investors confidence is positive
Pays a reliable dividend
Future
Future
Earnings are forecast to grow
Trading below its fair value
ABBV Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ABBV Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayPFE
24.23
-0.70%
NVS
130.77
+0.58%
LLY
819.38
-0.90%
SNY
50.02
+2.17%
TEVA
19.63
-0.76%
What is ABBV current stock price?
What are ABBV stock strengths?
What risks are associated with ABBV stock?
When is ABBV next earnings report?
What is ABBV market cap and volume?
What is ABBV's current Stock IQ?
Should I buy ABBV stock right now?
Is ABBV a Strong Buy right now?
What does a 'Strong Buy' rating mean for ABBV?
What does a 'Strong Sell' rating mean for ABBV?
What factors influence ABBV's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+3.97%
-3.51%
-5.52%
-0.99%
+5.01%
ABBV
AbbVie
Current Price
$226.87
Stock Insights
Strengths
Earnings are forecast to grow
Trading below its fair value
Investors confidence is positive
Pays a reliable dividend
Technical Indicators
5+ Days Down
Linked to ABBV
PFE
24.23
-0.70%
NVS
130.77
+0.58%
LLY
819.38
-0.90%
SNY
50.02
+2.17%
TEVA
19.63
-0.76%
Login to unlock AbbVie (ABBV) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$222.47 (+1.98%)
$190.83 (+18.89%)
$185.72 (+22.16%)
$201.5 (+12.59%)
ABBV Analysts Opinion
ABBV Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a strong earnings
Above analyst estimates
Revenue increase YoY
Earnings increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Investors confidence is positive
Pays a reliable dividend
Future
Future
Earnings are forecast to grow
Trading below its fair value
ABBV Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ABBV Street view is extremely bullish and have positive views on the near-term outlook
ABBV has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Investors losing confidence
Average key support and resistance price levels.
Login to displayABBV Latest Analysis
Cantor Fitzgerald Reaffirms Overweight Rating on AbbVie (ABBV). AbbVie Inc. (NYSE:ABBV) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. A global pharmaceutical company AbbVie Inc. (NYSE:ABBV) is among the best dividend stocks in the healthcare sector. On October 14 Cantor Fitzgerald reaffirmed its Overweight rating and $250 price target for AbbVie Inc. (NYSE:ABBV) while revising its earnings model to [….]
Today
AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know. The latest trading day saw AbbVie (ABBV) settling at $226.22 representing a -1.27% change from its previous close.
Wed Oct 15, 2025
Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?. ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humiras decline as Q3 results approach.
Tue Oct 14, 2025
AbbVie Gets FDA Approval To Expand RINVOQ Use For Ulcerative Colitis And Crohns Disease . (RTTNews) - AbbVie (ABBV) Monday announced the United States Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ (upadacitinib) for the treatment of adults with moderately to severely active ulcerative
Mon Oct 13, 2025
Ex-Dividend Reminder: Abbott Laboratories AbbVie and ARMOUR Residential REIT . Looking at the universe of stocks we cover at Dividend Channel on 10/15/25 Abbott Laboratories (Symbol: ABT) AbbVie Inc (Symbol: ABBV) and ARMOUR Residential REIT Inc. (Symbol: ARR) will all trade ex-dividend for their respective upcoming dividends. Abbott Laboratories will
Mon Oct 13, 2025
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors. New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic colorectal and solid tumors highlight progress in AbbVies growing ADC portfolio designed to target difficult-to-treat cancers. NORTH CHICAGO Ill. Oct. 13 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today...
Mon Oct 13, 2025
Carolina Wealth Trims Its AbbVie Stake to Nearly Nothing. Key PointsCarolina Wealth Advisors sold 38267 AbbVie shares. estimated transaction value ~$7.79 million based on quarterly average price
Thu Oct 9, 2025
Cantor Fitzgerald raises Abbvie stock price target to $250 on strong Skyrizi performance.
Thu Oct 9, 2025
Cramers Absolute Favorite AbbVie Rises After Study Completions and Upgrade. AbbVie Inc. (NYSE:ABBV) is one of Jim Cramers Recession-Proof Stock Picks. Cramer calls the stock his absolute favorite and it is followed by updates on the completion of two key studies. At the beginning of this month AbbVie Inc. (NYSE:ABBV) announced the completion of a key study on ABBV-101s food interaction and a Phase 2 [….]
Wed Oct 8, 2025
AbbVie Inc. (ABBV) Starts Building $70 Million Expansion of Its AbbVie Bioresearch Centre in Worcester Massachusetts. With significant hedge fund interest and trending on Reddit AbbVie Inc. (NYSE:ABBV) secures a spot on our list of the 10 Best Non-Tech Stocks to Buy According to Reddit. As part of its $10 billion United States capital expenditure strategy to increase biologics manufacturing capacity AbbVie Inc. (NYSE:ABBV) started building a $70 million expansion of its [….]
Wed Oct 8, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ABBV Stock trends
ABBV Stock performance
ABBV Stock analysis
ABBV investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings
Leaders